🔬 EditCo Bio will focus on delivering edited cells and optimized guide RNA designs for basic research and drug discovery.
🔀 Synthego will continue its focus on synthesizing high-quality guide RNA across various applications from basic research to clinical applications.
💼 John Tan, former Synthego President and COO, will be the CEO of EditCo Bio.
👥 Craig Christianson will step in as the new CEO of Synthego.
Introduction:
Synthego, a Silicon Valley-based company known for providing various CRISPR solutions to researchers across various disciplines, has announced that it will focus on its high-quality CRISPR guide RNA products and services business to support CRISPR therapeutic development. As part of this shift, Synthego has spun out its Engineered Cells and Eclipse business into a new company called EditCo Bio which will focus on supporting researchers in basic research and drug discovery. EditCo will operate independently with support from life sciences investment firm Telegraph Hill Partners.
Main points:
- The new CRISPR-based biotech company, EditCo Bio, will focus on delivering CRISPR edited cells and optimized guide RNA designs for CRISPR-based research.
- Synthego will now solely focus on providing high-quality CRISPR guide RNA and services for CRISPR therapeutic development.
- Craig Christianson will step in as the new CEO of Synthego, while former Synthego President and COO John Tan becomes CEO of EditCo Bio.
- EditCo Bio will operate independently with support from Telegraph Hill Partners.
- By splitting their focus, Synthego and EditCo Bio aim to better serve the needs of the CRISPR research and therapeutic communities.
Conclusion:
Synthego’s decision to spin out EditCo Bio and focus solely on providing CRISPR guide RNAs for CRISPR therapeutic development reflects the company’s commitment to supporting the rapidly growing field of CRISPR. By splitting their efforts, both Synthego and EditCo Bio can dedicate more resources and expertise to meeting the specific needs of their respective markets, potentially accelerating advancements in the field of genome engineering.
